Biomarin Pharmaceutical Stock News

The FDA has approved BioMarin Pharmaceutical Inc''s (NASDAQ: BMRN ) Voxzogo (vosoritide) for Injection for achondroplasia. The approval comes for achondroplasia patients five years and older to increase linear growth in patients with open epiphyses (growth plates). This indication is approved under accelerated Full story available on Benzinga.com

1st Therapeutic Treatment for Achondroplasia, Most Common Form of Disproportionate Short Stature

Marshall Wace North America L.P. bought a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 33,833 shares of the biotechnology companys stock, valued at approximately $2,823,000. Several other institutional investors have also recently bought and []

The FDA has approved BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) Voxzogo (vosoritide) for Injection for achondroplasia. The approval comes for achondroplasia patients five years and older to incre

(PR-inside.com) SAN DIEGO, CA / ACCESSWIRE / November 18, 2021 / Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) securities between January 13, 2020 and September 3, 2021, for violations of the Securities Exchange Act of 1934. BioMarin develops and commercializes therapies for people with serious and life-threatening rare disease and medical conditions. One of its product candidates is BMN 307, an AAV5 mediated gene therapy, which is in a phase 1/2 clinical trial to normalize blood phenylalanine ..

Voxzogo could reach blockbuster status with sales of $1 billion Related Stocks: BMRN , ASND , BBIO , PFE ,

Inspirion Wealth Advisors LLC lifted its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 10.9% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,655 shares of the biotechnology companys stock after purchasing an additional 557 shares during the period. Inspirion Wealth Advisors LLCs holdings []

Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against BioMarin Pharmaceutical Inc. in the United States District Court for the Northern District of California, on behalf of a class consisting of all persons and entities that []

BioMarin Pharmaceutical Inc. ( BMRN , Financial) investors could be in for a surprise according to a client note by SVB Leerink analyst Joseph Schwartz. FiercePharma reported that after polling physic

Related Stocks: KNTE , CNTA , TYRA , TNGX , BPMC , FULC , TPTX , IOVA , SGEN , AMRN , RACA , KDMN , AGEN , BMRN ,

BioMarin Pharmaceutical (NASDAQ:BMRN) had its target price raised by SVB Leerink from $108.00 to $112.00 in a report released on Monday morning, PriceTargets.com reports. They currently have an outperform rating on the biotechnology companys stock. A number of other research analysts have also recently weighed in on the stock. Jefferies Financial Group assumed coverage on []

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / November 15, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?prid=21204&wire=1Lead Plaintiff Deadline: December 22, 2021Class Period: January 13, 2020 - September 3, 2021 Allegations against BMRN include that: (i) BMN 307, an Adeno-Associated Virus Vector-Mediated Gene Transfer of ..

BioMarin Pharmaceutical (NASDAQ:BMRN) had its price objective lifted by analysts at SVB Leerink from $108.00 to $112.00 in a research report issued to clients and investors on Monday, Stock Target Advisor reports. The brokerage currently has an outperform rating on the biotechnology companys stock. SVB Leerinks price objective indicates a potential upside of 37.04% from []

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences. Among the